Valuation: Ocular Therapeutix, Inc.

Market Cap 2.2B 1.93B 1.82B 1.66B 3.11B 211B 3.13B 21.77B 8.44B 107B 8.25B 8.07B 349B P/E 2026 *
-6.59x
P/E 2027 * -7.05x
Enterprise Value 1.82B 1.6B 1.5B 1.38B 2.57B 174B 2.59B 18.02B 6.99B 88.86B 6.83B 6.68B 289B EV / Sales 2026 *
34.4x
EV / Sales 2027 * 20.8x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day-1.80%
1 week-0.51%
Current month-6.39%
1 month-11.37%
3 months-2.92%
6 months+21.23%
Current year-19.11%
1 week 9.6
Extreme 9.6
10.61
1 month 9.6
Extreme 9.6
11.48
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 14/04/2024
Director of Finance/CFO 50 19/01/2026
Chief Tech/Sci/R&D Officer 49 19/05/2024
Director TitleAgeSince
Chairman 57 30/06/2019
Director/Board Member 78 04/11/2012
Director/Board Member 66 19/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Sell

Chief Operating Officer

-1,099 0.0005%
25/08/26 Don

Chief Executive Officer

-100,184 0.0473%
24/08/26 Sell

Executive/Senior Manager

-3,035 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-1.80%-0.51%-19.84%+207.84% 2.2B
+2.68%+3.87%+58.22%+114.68% 1,026B
+0.56%+1.27%+53.29%+68.65% 649B
+0.02%+0.99%+19.10%+73.58% 468B
+0.06%+0.25%+37.03%+45.71% 352B
+1.16%+4.10%+21.99%+29.39% 271B
-0.24%+2.18%+10.14%+12.26% 256B
-0.01%+7.89%+41.57%+51.68% 220B
-1.11%+1.36%+30.85%+99.56% 188B
+0.30%-7.19%-32.43%-60.56% 170B
Average -0.11%+1.26%+21.99%+64.28% 360.13B
Weighted average by Cap. +0.13%+1.26%+37.26%+67.76%

Financials

2026 *2027 *
Net sales 52.93M 46.51M 43.8M 40.04M 74.84M 5.08B 75.48M 525M 203M 2.59B 199M 194M 8.4B 102M 90.06M 84.81M 77.53M 145M 9.83B 146M 1.02B 394M 5.01B 385M 376M 16.27B
Net income -334M -294M -277M -253M -473M -32.07B -477M -3.31B -1.29B -16.34B -1.26B -1.23B -53.09B -324M -285M -268M -245M -459M -31.12B -463M -3.22B -1.25B -15.85B -1.22B -1.19B -51.51B
Net Debt -378M -332M -313M -286M -534M -36.27B -539M -3.75B -1.45B -18.47B -1.42B -1.39B -60.03B -66M -58M -54.62M -49.93M -93.32M -6.33B -94.12M -654M -254M -3.23B -248M -242M -10.48B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
24/09/26 US$9.820 -1.80% 1,864,545
23/09/26 US$10.00 -4.76% 2,089,389
22/09/26 US$10.50 +5.11% 2,495,300
21/09/26 US$9.990 0.00% 2,073,006
18/09/26 US$9.990 -1.48% 4,100,930
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.00USD
Average target price
27.09USD
Spread / Average Target
+170.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock